A neuroprotective protein, ADNP, an eight amino acid long peptide has completed Phase ΙΙ clinical trials (clinical trial: NCT00505765) for IN treatment at 5 and 30 mg/day of patients with mild cognitive impairment, schizophrenia and Alzheimer disease based on experiments performed in mice using 0.5–2 μg/mouse/day)59,60. Here, ADNP is linked to early-onset autosomal dominant Alzheimer disease.